News
MBX
68.57
+2.22%
1.49
13D Filings
Barron‘s · 1d ago
MBX Biosciences Is Maintained at Buy by Truist Securities
Dow Jones · 5d ago
MBX Biosciences Price Target Raised to $88.00/Share From $70.00 by Truist Securities
Dow Jones · 5d ago
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88
Benzinga · 5d ago
MBX Biosciences price target raised to $88 from $70 at Truist
TipRanks · 5d ago
Weekly Report: what happened at MBX last week (0803-0807)?
Weekly Report · 5d ago
MBX Biosciences, Inc. (MBX) Gets a Buy from Mizuho Securities
TipRanks · 08/07 20:55
MBX Biosciences price target raised to $88 from $70 at Barclays
TipRanks · 08/07 10:21
Analysts Offer Insights on NA Companies: BillionToOne, Inc. Class A (BLLN) and MBX Biosciences, Inc. (MBX)
TipRanks · 08/06 16:50
MBX Biosciences reports Q2 EPS (78c), consensus (59c)
TipRanks · 08/06 13:27
MBX Biosciences Advances Canvuparatide and Obesity Pipeline
TipRanks · 08/06 12:41
MBX Biosciences GAAP EPS of -$0.78
Seeking Alpha · 08/06 12:19
MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) Estimate
Benzinga · 08/06 12:05
*MBX Biosciences 2Q Loss/Shr 78c >MBX
Dow Jones · 08/06 12:02
Press Release: MBX Biosciences Reports Second -2-
Dow Jones · 08/06 12:00
Press Release: MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
Dow Jones · 08/06 12:00
Top MBX Biosciences Insider Makes Notable Stock Move
TipRanks · 08/06 02:09
Weekly Report: what happened at MBX last week (0727-0731)?
Weekly Report · 08/03 09:43
MBX Biosciences Is Maintained at Outperform by Mizuho
Dow Jones · 07/29 16:01
Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91
Benzinga · 07/29 15:50
More
Webull provides a variety of real-time MBX stock news. You can receive the latest news about MBX Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About MBX
MBX Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. It is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency.